Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia

References

• Mead GM, Sydes MR, Walewski J, . An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002;13:1264–1274.
   PubMed Web of Science ®Google Scholar
• Magrath I, Adde M, Shad A, . Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996;14:925–934.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, O’Brien S, . Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569–1580.
   PubMed Web of Science ®Google Scholar
• Kelly JL, Toothaker SR, Ciminello L, . Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma 2009;9:307–310.
   PubMedGoogle Scholar
• Divine M, Casassus P, Koscielny S, . Burkitt lymphoma in adults:a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol 2005;16:1928–1935.
   PubMed Web of Science ®Google Scholar
• Lee EJ, Petroni GR, Schiffer CA, . Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia:results of Cancer and Leukemia Group B study 9251. J Clin Oncol 2001;19:4014–4022.
   PubMed Web of Science ®Google Scholar
• Burkitt D. Long-term remissions following one and two-dose chemotherapy for African lymphoma. Cancer 1967;20:756–759.
   PubMed Web of Science ®Google Scholar
• Traore F, Coze C, Atteby JJ, . Cyclophosphamide monotherapy in children with Burkitt lymphoma:a study from the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer 2011;56:70–76.
   PubMed Web of Science ®Google Scholar
• Gladstone DE, Bolaños-Meade J, Huff CA, . High-dose cyclophosphamide and rituximab without stem cell transplant:a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leuk Lymphoma 2011;52:2076–2081.
   PubMed Web of Science ®Google Scholar
• Brodsky RA. High-dose cyclophosphamide for autoimmunity and alloimmunity. Immunol Res 2010;47:179–184.
   PubMed Web of Science ®Google Scholar
• DeZern AE, Petri M, Drachman DB, . High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases. Medicine (Baltimore) 2011;90:89–98.
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Jones RJ. Aplastic anaemia. Lancet 2005;365:1647–1656.
   PubMed Web of Science ®Google Scholar
• Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009;6:638–647.
   PubMed Web of Science ®Google Scholar
• Anderson JR, Wilson JF, Jenkin DT, . Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 1983;308:559–565.
   PubMed Web of Science ®Google Scholar
• Mazza JJ, Hines JD, Andersen JW, . Aggressive chemotherapy in the treatment of Burkitt's and non-Burkitt's undifferentiated lymphoma. Leuk Lymphoma 1995;18:289–296.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, . WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC;2008.
   Google Scholar
• National Cancer Institute Common Terminology Criteria, version 3.0. 2006. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Cortes J, O’Brien S, . Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999;17:2461–2470.
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509.
   Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244–1253.
   PubMed Web of Science ®Google Scholar
• Li S, Lin P, Fayad LE, . B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 2012;25:145–156.
   PubMed Web of Science ®Google Scholar
• Nitta E, Izutsu K, Sato T, . A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 2007;18:364–369.
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Johnson JL, Niedzwiecki D, . Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer 2004;100:1438–1448.
   PubMed Web of Science ®Google Scholar
• LaCasce A, Howard O, Li S, . Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma 2004;45:761–767.
   PubMed Web of Science ®Google Scholar
• Corazzelli G, Frigeri F, Russo F, . RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and “unclassifiable” highly aggressive B-cell lymphoma. Br J Haematol 2012;156:234–244.
   PubMed Web of Science ®Google Scholar
• Barta SK, Lee JY, Kaplan LD, . Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer 2011 Dec 16. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Noy A, Kaplan L, Lee J. Feasibility and toxicity of a modified dose intensive R-CODOX-M/IVAC for HIV-associated Burkitt and atypical Burkitt lymphoma (BL): preliminary results of a prospective multicenter phase II trial of the AIDS Malignancy Consortium (AMC). Blood 2009;114(Suppl. 1): Abstract 3673.
   Google Scholar
• Meinhardt A, Burkhardt B, Zimmermann M, . Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol 2010;28:3115–3121.
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Johnson JL, Byrd JC, . Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt-like leukemia/lymphoma: Cancer and Leukemia Group B (CALGB) Study 10002. Blood 2010;116(Suppl. 1): Abstract 858.
   Google Scholar
• Barnes BA, LaCasce AS, Feng Y, . Rituximab added to CODOX-M/IVAC has no clear benefit compared to CODOX-M/ IVAC alone in adult patients with Burkitt lymphoma. Blood 2009;114(Suppl. 1): Abstract 1667.
   PubMed Web of Science ®Google Scholar